Evaluation of the efficacy of a food supplement in reducing dry eye symptoms
| ISRCTN | ISRCTN15920416 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN15920416 |
| Clinical study protocol | NT0000234-25 |
| Sponsor | ROELMI HPC SRL (Italy) |
| Funder | ROELMI Srl |
- Submission date
- 13/11/2026
- Registration date
- 20/11/2026
- Last edited
- 16/11/2026
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Giovanna Lionetti
Principal investigator
Principal investigator
Via Palmiro Togliatti,28H
Cirò Marina (KR)
88811
Italy
| Phone | +39 (0)3286155993 |
|---|---|
| lionettigiovanna@libero.it |
Dr Roberta Villa
Public, Scientific
Public, Scientific
Viale Indipendenza, 11
Pavia
27100
Italy
| Phone | +39 (0)38225504 |
|---|---|
| roberta.villa@complifegroup.com |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Blinded (masking used) |
| Control | Placebo |
| Assignment | Parallel |
| Purpose | Treatment, Efficacy |
| Scientific title | Clinical evaluation of the efficacy of a food supplement in reducing dry eye symptoms: a randomized, double-blind, parallel-group, placebo-controlled study |
| Study objectives | |
| Ethics approval(s) |
Approved 16/05/2025, Independent Ethics Committee for Non-Pharmacological Clinical Investigations (Italian Scientific Society for Non-Pharmacological Clinical Investigations, Via XX Settembre 30/4, Genova, 16121, Italy; +39 (0)10 5454842; a.scudieri@studinonfarmacologici.it), ref: 2025/10 |
| Health condition(s) or problem(s) studied | Dry eye |
| Intervention | The study will be a double-blind, randomized, parallel-group, placebo-controlled clinical study. Half of the subjects will take the active product EXCEPTIONHYAL® WINK containing sodium hyaluronate and half of the subjects will take a placebo for 56 days (T0 to T56). A restricted randomization list will be generated by an independent technician using the appropriate algorithm ("Wei's urn") of the PASS 11 software (PASS, LLC, Kaysville, UT, USA) and stored in a secure location. The principal investigator or his delegate will dispense the products according to the generated randomization list. Subjects will take one capsule a day in the morning, on an empty stomach, with a glass of water. |
| Intervention type | Supplement |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) | |
| Completion date | 26/09/2025 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 64 Years |
| Sex | All |
| Target sample size at registration | 66 |
| Total final enrolment | 66 |
| Key inclusion criteria | 1. Healthy male and female subjects 2. Caucasian ethnicity 3. Subjects aged between 18 and 64 years (extremes included) 4. Subjects suffering from dry eye discomfort* 5. 34 subjects wear contact lenses, while 32 subjects wear glasses or have normal vision and do not need glasses or contact lenses 6. Subjects registered with National Health Service (NHS) 7. Subjects certifying the truthfulness of the personal data disclosed to the investigator 8. Subjects able to understand the language used in the investigation center and the information given by the investigator 9. Subjects able to respect the instructions given by the investigator as well as able to respect the study constraints and specific requirements 10. Commitment not to change the daily routine or the lifestyle 11. Stable pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) for at least 1 month without any changes expected or planned during the study 12. Subjects informed about the test procedures who have signed a consent form and privacy agreement *At T0 Ocular Surface Disease Index (ODSI) between 13 and 32 and Dry Eye Questionnaire 5 (DEQ-5) between 6 and 12. ODSI: is a 12-item questionnaire to assess dry eye symptoms and their impact on vision-related function over the past week. It consists of three subscales: ocular symptoms, vision-related function, and environmental triggers. Subjects rate each item on a scale from 0 to 4. Based on the total score, symptoms are classified as follows: normal (0–12), mild dry eye (13–22), moderate dry eye (23–32), severe dry eye (33–100). DEQ-5: is a 5-item questionnaire assessing symptoms experienced in the past month. It evaluates frequency of watery eye, discomfort, and dryness (scored on a 0–4 scale) and intensity of late-day discomfort and dryness (scored on a 0–5 scale). A total score greater than 6 indicates the presence of dry eye, while a score greater than 12 may require further investigation to exclude the possibility of Sjögren's syndrome. |
| Key exclusion criteria | 1. Subjects who do not meet the inclusion criteria 2. Subjects wearing glasses with blue light-blocking lenses 3. Subjects with any acute, chronic, or progressive disease or condition that may interfere with the study data or that the investigator considers dangerous to the subject or incompatible with the requirements of the study 4. Subjects participating or planning to participate in other clinical trials 5. Subjects who participated in a similar study without respecting an adequate washout period (at least 1 month) 6. Subjects that have food intolerances or food allergies to ingredients of the study product 7. Subjects under pharmacological treatments that are considered incompatible with the study requirement by the investigator* 8. Subjects who are currently using food supplement(s) and/or topical products (i.e. eye drops) with the same activity as the study product, or who haven't observed an adequate washout period (at least 1 month)** 9. Subjects admitted to a health or social facility 10. Subjects planning a hospitalization during the study 11. Subjects not able to be contacted in case of emergency 12. Subjects deprived of freedom by administrative or legal decision or under guardianship 13. Subjects with a history of drug, alcohol and other substance abuse 14. Subjects with eating disorders (i.e. bulimia, psychogenic eating disorders, etc) 15. Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (for the women of childbearing potential) *Systemic medications that stimulate tear secretion (e.g., pilocarpine, cevimeline) **Topical ophthalmic medications (corticosteroids, NSAIDs, and cyclosporine); supplements containing omega-3, vitamin A, vitamin E, lutein, zeaxanthin, and lactoferrin |
| Date of first enrolment | 16/05/2025 |
| Date of final enrolment | 28/05/2025 |
Locations
Countries of recruitment
- Italy
Study participating centre
Nutratech SRL
Via Francesco Todaro 20/22
Rende
87036
Italy
Rende
87036
Italy
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
16/11/2026: Study's existence confirmed by the Independent Ethics Committee for Non-Pharmacological Clinical Investigations.